Table 3.
Odds ratios (95%CI) | P | Adjusted Odds ratios (95% CI)a | P | |
---|---|---|---|---|
Effect of PDR on overanticoagulationb | ||||
Co-trimoxazole | ||||
PDR applied, INR >4.5 | 0.10 (0.02–0.50) | 0.005* | 0.06 (0.01–0.51) | 0.010* |
PDR applied, INR >6.0 | 0.10 (0.01–1.02) | 0.051 | 0.09 (0.01–0.92)c | 0.042* |
PDR not applied | Reference | Reference | ||
Other antibiotics | ||||
PDR applied, INR >4.5 | 0.70 (0.32–1.52) | 0.37 | N.A.d | |
PDR applied, INR >6.0 | 1.36 (0.47–3.93) | 0.57 | N.A | |
PDR not applied | Reference | |||
Risk of overanticoagulation | ||||
PDR not applied | ||||
Co-trimoxazole, INR >4.5 | 4.52 (1.56–13.1) | 0.006* | 3.96 (1.33–11.8) | 0.013* |
Co-trimoxazole, INR >6.0 | 5.43 (1.53–19.2) | 0.009* | 3.86 (1.03–14.6) | 0.046* |
Other antibiotics | Reference | Reference | ||
PDR applied | ||||
Co-trimoxazole, INR >4.5 | 0.68 (0.17–2.73) | 0.59 | N.A. | |
Co-trimoxazole, INR >6.0 | 0.41 (0.04–3.66) | 0.42 | 0.30 (0.03–3.05)e | 0.30 |
Other antibiotics | Reference | Reference |
*Statistically significant difference at P ≤ 0.05
aAdjusted for differences in fever as indicated by patient, age, sex, target therapeutic range, unless otherwise indicated
bPDR, Preventive dose reduction
cAdjusted for differences in age and sex
dN.A., Adjustment not applied because the inclusion of covariates in our model did not result in a change of at least 5% in the odds ratios (see text)
eAdjusted for differences in age, sex and fever as indicated by patient